Small-cap stocks with improving money flow, Wed Jan 14th - #XOMA #WBTN #TBPH #SABS #ACHV #BOOM #CHCO #FOSL #GNPX #IMCC #KXIN #MAZE #NEWT #ORMP #UA #RYAM #PKST #NGVC #LXFR #GCO #FCRS #DCO #CC #ADNT - More: crystalequityresearch.com/trade-alerts... - #smallcap

Oramed and Lifeward Announce Strategic Transaction Oramed Pharmaceuticals and Lifeward (NASDAQ: LFWD) signed binding agreements dated January 13, 2026 to transfer Oramed's POD™ oral drug delivery platform to Lifeward in exchange for Oramed receiving a 49.9% beneficial ownership interest upon satisfaction of closing conditions. Lifeward will issue two $10 million senior secured convertible notes (8% interest) with 100% warrant coverage; Oramed to invest $9M in each note. Oramed will fund and manage the upcoming clinical trial and receive 4% of net ReWalk sales for up to 10 years. Lifeward reported $26M revenue from ReWalk and AlterG in the last four quarters.

#LFWD #ORMP Oramed and Lifeward Announce Strategic Transaction

www.stocktitan.net/news/LFWD/oramed-and-lif...

#ORMP: Advancing Clinical Activities, Generating Gains From Investment Portfolio, New Rights Plan Adopted buff.ly/L9HRhy9

Oramed Reports Fiscal Third Quarter 2025 Financial Results NEW YORK, Nov. 17, 2025/ PRNewswire/-- Oramed Pharmaceuticals Inc., a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ended September 30, 2025.. Net income of $65.0 million, compared to a net loss of $6.1 million in the same period...

#ORMP Oramed Reports Fiscal Third Quarter 2025 Financial Results

www.stocktitan.net/news/ORMP/oramed-reports...

Small-cap stocks with improving money flow, Tue Nov 11th - #STAA #ORMP #ADSE #BCIC #CECO #DSGN #EWTX #GANX #HCAI #INNV #PUBM #NTHI #YEXT #VAN #SFL #NVRI #KOP #FIGS #DV #BAK - More: crystalequityresearch.com/leading-indi... - #smallcap

Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives Oramed (Nasdaq: ORMP) reported strategic progress on its oral insulin program, investment gains, and cash growth as of September 30, 2025. The company will run a 60‑patient U.S. trial focused on high‑responder subgroups that showed potential >1% HbA1c reduction. A prior joint venture with Hefei Tianhui Biotech was terminated; Oramed will continue development independently. Oramed described a diversified investment portfolio with material realizations and paper gains (Scilex structured investment returning $95.5M to date with ~ $60M expected in next 12 months; Alpha Tau position valued at ~$64.8M; Pelthos position up ~180%). Cash and assets rose from $155.7M (Jan 2023) to ~$210M (Sep 30, 2025) (unaudited).

#ORMP Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

www.stocktitan.net/news/ORMP/oramed-release...

With Substantial Liquidity, #ORMP Has Generated Gains & Income From Investment Portfolio buff.ly/21CyOnj

Major Biotech Deal: Alpha Tau Medical Secures $36.9M Investment to Accelerate Cancer Treatment Innovation Strategic partnership combines oral drug delivery expertise with alpha-radiation cancer therapy. New funding accelerates US trials and manufacturing. Learn expansion plans.

#DRTS #ORMP Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

www.stocktitan.net/news/DRTS/oramed-pharmac...

#ORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 Trial buff.ly/Ds2CqX7

Oramed Pharmaceuticals Issues Letter to Shareholders Oramed Pharmaceuticals (NASDAQ: ORMP) has announced key developments expected for completion in 2025, centered around its new joint venture OraTech Pharmaceuticals. The venture focuses on oral insulin development with planned U.S. Phase 3 trials.Key highlights include:Distribution of majority OraTech holdings to Oramed shareholders via dividend, coinciding with OraTech's planned Nasdaq listingPlanned cash dividend of approximately $0.25 per shareMarketing Authorization Application submitted by HTIT for oral insulin capsule in China, with OraTech expected to receive royaltiesOngoing revenue from Scilex partnership, including $400,000 in royalties due for Q4 2024The company maintains a strong financial position through its Scilex transaction, receiving $70 million from a $99.5 million loan agreement, with additional $53 million expected over two years. Oramed holds 12.25 million Scilex shares, increasing to 18.75 million shares, plus royalty streams from multiple products including ZTlido, ELYXYB, and GLOPERBA.

#ORMP Oramed Pharmaceuticals Issues Letter to Shareholders

www.stocktitan.net/news/ORMP/oramed-pharmac...

Brad Knott has filed three #stock trades, including two $CMPO purchases and an $ORMP sale

#ORMP #CMPO #insidertrading #insidealert #congresstrading #stockmarket #finsky #econsky

Oral Insulin Breakthrough: $75M Deal Positions Oramed's Revolutionary Drug Delivery Platform for Global Launch Oramed launches OraTech Pharmaceuticals with $75M backing, securing manufacturing partnership and advancing oral insulin development with revised Phase 3 trial.

#ORMP Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

www.stocktitan.net/news/ORMP/oramed-announc...